A natural compound composition for improving myocardial energy metabolism, its preparation method and application

By using a compound composition of natural ingredients such as deacetylated cypermethrin, NAMPT expression is enhanced and NAD+ salvage synthesis is promoted, which solves the problem of insufficient systemic regulation of myocardial energy metabolism disorders in existing technologies, and achieves multi-level recovery of myocardial energy metabolism and long-term intervention with good safety.

CN123101550APending Publication Date: 2026-11-17FUWAI HOSPITAL CHINESE ACAD OF MEDICAL SCI & PEKING UNION MEDICAL COLLEGE
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202611507152.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-09-28
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Existing technologies have limited single-component action targets and overall regulatory capacity, raising concerns about the safety of long-term use. They also lack systematic intervention strategies for myocardial energy metabolism disorders and lack myocardial-specific design.

Method used

Using deacetylated shikimic acid as the core ingredient, combined with 5-O-caffeoyl shikimic acid, neolansinoside, coreopyridine and puerarin, a multi-target, multi-level natural compound composition is formed. By increasing the expression of nicotinamide phosphoribosyltransferase (NAMPT) in cardiomyocytes, it promotes the salvage synthesis of NAD+ and restores the NAD+/NADH balance in the myocardium.

Benefits of technology

It significantly restores the NAD+/NADH balance of cardiomyocytes, achieves multi-level systemic regulation of myocardial energy metabolism, has good safety, is suitable for long-term use, and can effectively intervene before the silent damage to cardiac function occurs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123101550A_ABST
    Figure CN123101550A_ABST
Patent Text Reader

Abstract

This invention relates to the field of pharmaceutical composition technology, and more particularly to a natural compound composition for improving myocardial energy metabolism, its preparation method, and its application. It comprises the following active ingredients: deacetylated arbutin, 5-O-caffeoylshikimic acid, neolansinoside, coreopyridine, and puerarin. This invention uses deacetylated arbutin as its core ingredient, which can significantly upregulate NAD in cardiomyocytes. + Expressing nicotinamide phosphoribosyltransferase, the key rate-limiting enzyme in the salvage synthesis pathway, promotes NAD at its source. + The generation of NAD+ in cardiomyocytes can effectively correct the formation of NAD+. + An imbalance of NAD+. Under pathological conditions, cardiomyocytes often experience an imbalance due to NAD+. + When the pool is depleted, leading to an energy supply crisis, this invention can restore the redox balance, rebuild the normal energy metabolism environment of myocardial cells, and provide a solid material basis for maintaining myocardial function.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the field of pharmaceutical composition technology, and in particular to a natural compound composition for improving myocardial energy metabolism, its preparation method and application. Background Technology

[0002] Heart failure is the end stage of many cardiovascular diseases. It is not a sudden event, but a chronic process that gradually evolves from myocardial metabolic disorders and subclinical functional decline to overt heart failure. It is worth noting that before the appearance of typical symptoms, many individuals already have underlying myocardial energy metabolism abnormalities and early decline in cardiac function. This stage is often overlooked due to the lack of obvious clinical manifestations and targeted interventions.

[0003] With the changing lifestyles of modern society, long-term sleep deprivation, circadian rhythm disorders, and shift work are becoming increasingly common. The persistent disruption of biological rhythms caused by these behaviors can interfere with the normal energy metabolism rhythm of the myocardium, increasing the heart's susceptibility to fluctuations in energy supply, thus constituting an important risk factor for occult cardiac damage. Existing research indicates that the transcription factor E4BP4 (also known as NFIL3) is a key link between circadian rhythm disorders and myocardial metabolic imbalances. E4BP4 can regulate factors including NAD+... + The abnormal expression of multiple metabolic genes, including those involved in salvage synthesis pathways, can directly lead to myocardial NAD when circadian rhythms are disrupted. + This invention addresses the issue of energy depletion and impaired energy metabolism. It utilizes a systematic screening of E4BP4, a target highly correlated with circadian rhythms, to precisely identify specific active ingredients from natural products that regulate E4BP4, and further develops related compositions. However, this population often presents with no clinical symptoms in the early stages, making functional abnormalities difficult to identify through routine physical examinations. Currently, there is a lack of early prevention strategies suitable for this stage. Therefore, developing functional myocardial protective products that are safe and feasible for long-term use for the aforementioned sub-healthy and subclinical populations has clear and urgent practical significance.

[0004] As a high-energy-consuming organ, the normal function of the heart is highly dependent on a sufficient and stable energy supply. Nicotinamide adenine dinucleotide (NAD) + As a key coenzyme in cellular energy metabolism, NAD+ is widely involved in core energy-producing processes such as the tricarboxylic acid cycle and oxidative phosphorylation. Its oxidized to reduced form ratio (NAD+) is crucial. + NADH (non-reduction complex) is considered a core indicator for measuring cellular redox state and energy metabolism levels. Studies have shown that NAD+ is prevalent in myocardial energy metabolism disorders. + Decreased levels and NAD +An imbalance in the NADH ratio directly leads to insufficient energy production by cardiomyocytes, becoming a crucial pathological basis for cardiac dysfunction. Nicotinamide phosphoribosyltransferase (NAMPT), as an NAD+... + The rate-limiting enzyme in the salvage synthesis pathway is crucial for maintaining intracellular NAD in cardiomyocytes. + Homeostasis plays a crucial regulatory role. Studies have shown that NAMPT is a downstream target protein of E4BP4 and is directly regulated by E4BP4. As a transcription factor, E4BP4 can bind to the promoter region of NAMPT, inhibiting NAMPT transcription, thereby leading to a decrease in NAMPT expression levels during circadian rhythm disruption, and consequently reducing NAD. + The synthesis of NAMPT. Therefore, by increasing NAMPT expression and restoring myocardial NAD, the synthesis of NAMPT can be improved. + NADH balance to improve energy supply is an important strategy for early intervention in cardiac dysfunction.

[0005] Existing treatments for NAD + Most metabolic intervention products focus on directly supplementing NAD. + Precursor substances, such as nicotinamide mononucleotide (NMN) and nicotinamide nucleoside (NR), are available, but these approaches have significant limitations: First, the target sites of a single component are limited, making it difficult to achieve systematic and multi-level regulation of the complex energy metabolism network of the myocardium, resulting in insufficient overall efficacy; second, the in vivo conversion efficiency and bioavailability of some precursors are not ideal, and the safety of long-term, high-dose use remains controversial; third, existing products generally lack myocardial-specific design and are not developed to address the pathological characteristics of myocardial energy metabolism disorders. Natural products, due to their wide availability, synergistic effects of multiple components, and relatively good long-term safety, have unique advantages in the development of functional products. However, there are currently no products specifically targeting myocardial NAD. + A compound formulation scientifically formulated with multiple natural active ingredients has been developed to regulate NADH metabolism. However, the effects of single natural ingredients are limited and cannot meet the comprehensive needs of global regulation of myocardial energy metabolism and early protection of cardiac function. Based on these issues, there is an urgent need to develop a formulation with natural products at its core that can effectively restore myocardial NAD+. + A compound composition that is NADH balanced, has good safety profile, and is suitable for long-term use, to fill a gap in existing technology. Summary of the Invention

[0006] The purpose of this invention is to provide a method for restoring myocardial NAD. + This is a natural product compound composition that balances NADH and improves myocardial energy metabolism, aiming to solve the problems of single-component single-target action, insufficient overall regulatory capacity, and doubts about the safety of long-term use in existing technologies.

[0007] To achieve the above-mentioned objectives, the present invention provides the following technical solution: This invention provides a natural compound composition for improving myocardial energy metabolism, comprising the following active ingredients: deacetylated shikimic acid, 5-O-caffeoyl shikimic acid, neolansinoside, coreopyridine, and puerarin.

[0008] Preferably, the weight parts of each active ingredient are: 40-80 parts of deacetylated shikimic acid, 5-20 parts of 5-O-caffeoyl shikimic acid, 5-20 parts of neolansinoside, 5-20 parts of coreopyridine, and 5-20 parts of puerarin.

[0009] Preferably, the weight parts of each active ingredient are: 60 parts of deacetylated shikimic acid, 10 parts of 5-O-caffeoyl shikimic acid, 10 parts of neolansinoside, 10 parts of coreopsis glycoside, and 10 parts of puerarin.

[0010] Preferably, the deacetylated cypermethrin is a deacetylated cypermethrin-cyclodextrin inclusion complex treated with cyclodextrin.

[0011] Preferably, the cyclodextrin is β-cyclodextrin or hydroxypropyl-β-cyclodextrin, and the molar ratio of deacetylated cyclodextrin to cyclodextrin is 1:1~2.

[0012] This invention provides a method for preparing the natural compound composition, comprising the following steps: (1) Take acetyl shikimic acid, 5-O-caffeoyl shikimic acid, neolansinoside, coreopyridine and puerarin by weight respectively, mix them evenly to obtain a mixture; (2) Add excipients to the mixture and mix to prepare a formulation.

[0013] Preferably, the deacetylated cypermethrin in step (1) is first subjected to cyclodextrin inclusion treatment before mixing, specifically including: weighing deacetylated cypermethrin and β-cyclodextrin in a molar ratio of 1:1~2, dissolving β-cyclodextrin in hot water at 50~60℃ to prepare a saturated solution, dissolving deacetylated cypermethrin in ethanol and then adding it dropwise to the β-cyclodextrin solution, stirring and collecting the precipitate to obtain deacetylated cypermethrin-β-cyclodextrin inclusion complex powder.

[0014] Preferably, the stirring is performed by first stirring at a constant temperature of 50-60°C for 2-4 hours, and then continuing to stir overnight after cooling.

[0015] This invention provides the application of the aforementioned natural compound composition in the preparation of functional products for improving myocardial energy metabolism.

[0016] Preferably, the functional product is used to improve myocardial energy metabolism disorders caused by circadian rhythm disorders, long-term sleep deprivation, or shift work.

[0017] This invention provides a method for restoring myocardial NAD +A NADH-balanced compound composition, wherein the main active ingredient is deacetylated shikimic acid, and it is formulated with 5-O-caffeoyl shikimic acid, neolansinoside, coreopterin, and puerarin, all five of which are of natural origin. The names, abbreviations, and descriptions of each active ingredient are as follows: Deacetylasperulosidic acid (DAA) is an iridoid glycoside; it is found in Rubiaceae plants such as Hedyotis diffusa and Noni fruit. 5-O-Caffeoylshikimic acid is a caffeoyl derivative of shikimic acid; found in various plants. Neolanancerin is a xanthonesin; it is also found in St. John's wort, Gentiana scabra, etc. Coreopsin is a chalcone glycoside found in plants of the genus Coreops, belonging to the Asteraceae family. Puerarin is an isoflavone glycoside; it is derived from kudzu root, a plant belonging to the genus *Pueraria* of the legume family. Significant synergistic effects exist among the components: deacetylated cytosolic acid, as the core active ingredient, enhances nicotinamide phosphoribosyltransferase (NAMPT, NAD) in cardiomyocytes. + The expression level of the rate-limiting enzyme in the salvage synthesis pathway is reduced, promoting NAD+ expression. + The salvage synthesis of NAD+ in cardiomyocytes restores their intracellular NAD+ synthesis. + The NADH ratio is improved, thus enhancing energy metabolism; the other four components act as synergistic active ingredients, working together at different stages to improve myocardial NAD. + The NADH metabolic network, in conjunction with deacetylated cypermethrin, produces a synergistic effect, achieving multi-level and systemic regulation of myocardial energy metabolism disorders.

[0018] Compared with the prior art, the present invention has the following beneficial effects: I. This invention uses deacetylated cypermethrin as its core component, which can significantly upregulate NAD in cardiomyocytes. + This invention targets the expression of nicotinamide phosphoribosyltransferase (NAMPT), a key rate-limiting enzyme in the salvage synthesis pathway. In specific experimental verification, primary mouse cardiomyocytes were cultured for 48 hours with 10 mM ISO and 30 mM of the candidate compound. Cell lysis was performed, and the cell lysates were analyzed by ELISA. The results showed a significant increase in NAMPT content. Subsequently, the active ingredients were mixed according to the aforementioned compound ratio and subjected to the same ELISA analysis. The results showed that the compound composition significantly enhanced NAMPT content compared to any single drug, further confirming the synergistic effect of the compound components. Through this mechanism, this invention promotes NAD at its source. + The generation of NAD+ in cardiomyocytes can effectively correct the formation of NAD+. +An imbalance of NAD+. Under pathological conditions, cardiomyocytes often experience an imbalance due to NAD+. + When the pool is depleted, leading to an energy supply crisis, this invention can restore the redox balance, rebuild the normal energy metabolism environment of myocardial cells, and provide a solid material basis for maintaining myocardial function.

[0019] II. This invention scientifically combines deacetylated cypermethrin with four functionally screened natural auxiliary ingredients, each of which acts on NAD+. + Different links in the metabolic network form a multi-target, multi-level synergistic regulatory system, with the expected overall effect significantly superior to any single ingredient, effectively overcoming the deficiency of existing products that target only one specific area. Furthermore, all active ingredients are derived from natural plants, exhibiting no adverse effects on cardiomyocytes at effective concentrations, demonstrating good safety and avoiding the risks associated with synthetic NAD+. + The potential controversies surrounding long-term use of precursors make them particularly suitable as preventative functional products requiring long-term use.

[0020] Third, this invention is specifically designed for high-risk groups of patients with latent cardiac function damage, such as those who frequently stay up late, have disrupted circadian rhythms, or work shifts. It allows for effective intervention before obvious clinical symptoms appear. The product has diverse dosage forms and a mature manufacturing process. The bioavailability of the core components can be improved through technologies such as cyclodextrin inclusion complexation. It exhibits good stability and ease of use, and has broad market application prospects. Attached Figure Description

[0021] To more clearly illustrate the technical solutions in the embodiments of the present invention or the prior art, the drawings used in the description of the embodiments or the prior art will be briefly introduced below. Obviously, the drawings described below are only embodiments of the present invention. For those skilled in the art, other drawings can be obtained based on the provided drawings without creative effort.

[0022] Figure 1 The compound composition of the present invention and its single active ingredient have effects on NAD in cardiomyocytes. + A bar chart illustrating the effect of the / NADH ratio, where the horizontal axis represents different experimental groups (NC is the normal control group, ISO is the damage model group, and the others are single-component groups of deacetylated shikimic acid, 5-O-caffeoyl shikimic acid, neolansinoside, puerarin, and the compound composition of this invention, respectively), and the vertical axis represents NAD+. + The NADH ratio, as shown in the figure, indicates that the recovery effect of the compound combination is significantly better than that of any single component.

[0023] Figure 2 The evaluation results of the improvement in central function in the Rev-Erbα / β double knockout (DKO) mouse model include: A shows representative echocardiographic images of different treatment groups before administration (0W) and 4 weeks after administration (4W); B represents the trend of left ventricular ejection fraction (LVEF); C represents the trend of change in left ventricular end-diastolic diameter (LVIDd); D represents the trend of changes in left ventricular end-systolic diameters (LVIDs). Detailed Implementation

[0024] The technical solutions provided by the present invention will be described in detail below with reference to the embodiments, but they should not be construed as limiting the scope of protection of the present invention.

[0025] The English abbreviations and their meanings used in this embodiment are as follows: DAA refers to deacetylasperulosidic acid; NAMPT refers to nicotinamide phosphoribosyltransferase; NAD... + NADH refers to reduced nicotinamide adenine dinucleotide; FAO refers to fatty acid oxidation; ISO refers to isoproterenol; ELISA refers to enzyme-linked immunosorbent assay; CCK-8 refers to cell counting kit-8.

[0026] All five active ingredients used in this invention are natural products, which can be purchased commercially or obtained through extraction and purification from corresponding plants, with a purity of not less than 95%. The names, abbreviations, structural types, and natural sources of each ingredient are listed below: Deacetylasperulosidic acid (DAA): an iridoid glycoside compound, mainly derived from Rubiaceae plants such as Hedyotis diffusa and Noni fruit. 5-O-Caffeoylshikimic acid: a caffeoyl derivative of shikimic acid, widely found in various plants; Neolancerin: a xanthonesin glycoside derived from plants such as St. John's wort and Gentiana scabra; Coreopsin: a chalcone glycoside compound derived from plants in the Asteraceae family, such as Coreopsin. Puerarin: an isoflavone glycoside derived from the root of the kudzu plant (Pueraria lobata), a member of the legume family.

[0027] Example 1

[0028] This embodiment provides a method for restoring myocardial NAD. + A natural product complex composition with NADH balance, wherein the active ingredients are weighed as follows: 60 g of deacetylated shikimic acid, 10 g of 5-O-caffeoyl shikimic acid, 10 g of neolansinoside, 10 g of coreopyridine, and 10 g of puerarin.

[0029] The preparation method is as follows: (1) Weigh out the five active ingredients precisely according to the above prescription and set aside; (2) The five raw materials are put into the three-dimensional mixer in sequence and mixed at 20 r / min for 30 minutes until homogeneous to obtain the compound active mixture; (3) Add microcrystalline cellulose (20% of the total weight of the mixture) and magnesium stearate (0.5% of the total weight of the mixture) to the mixture and continue mixing for 10 minutes; (4) The above materials are made into 20-mesh granules using a dry granulation process; (5) Fill the granules into empty capsule shells, each capsule containing 0.45 g, to obtain the capsule-form compound composition.

[0030] Example 2

[0031] This embodiment provides another compound composition with the following dosage: 40 g of deacetylated shikimic acid, 20 g of 5-O-caffeoyl shikimic acid, 20 g of neolansinoside, 10 g of coreopyridine, and 10 g of puerarin.

[0032] The preparation method is as follows: (1) Weigh each active ingredient according to the above prescription amount; (2) Place the above ingredients in a V-type mixer and mix at 25 r / min for 40 minutes; (3) Add pregelatinized starch (15% of the total weight of the mixture) and crospovidone (3% of the total weight of the mixture), and continue mixing for 15 minutes; (4) Add an appropriate amount of purified water to prepare a soft material, granulate it through an 18-mesh sieve, and dry it in a 50°C forced-air drying oven until the moisture content is less than 5%; (5) After granulation, add magnesium stearate (0.8% of the total weight of the granules) and mix well; (6) The tablets are compressed into tablets using a tablet press, each weighing 0.5 g, to obtain the tablet-type compound composition.

[0033] Example 3

[0034] This embodiment provides a compound composition with a high proportion of core ingredients, and the dosage of each ingredient is as follows: 80 g of deacetylated shikimic acid, 5 g of 5-O-caffeoylshikimic acid, 5 g of neolansinoside, 5 g of coreopyridine, and 5 g of puerarin.

[0035] The preparation method is as follows: (1) Weigh each ingredient according to the above prescription; (2) Deacetylated cypermethrin and the other four auxiliary ingredients were passed through an 80-mesh sieve and then put into a trough mixer and mixed at 30 r / min for 45 minutes. (3) Add lactose (25% of the total weight of the mixture) to the mixture as a filler and sodium carboxymethyl starch (4% of the total weight of the mixture) as a disintegrant, and continue mixing for 10 minutes; (4) Wet extrusion granulation is used, and the granules are dried and then granulated; (5) Dispense the granules into aluminum-plastic composite film bags at a rate of 3 g per bag to obtain the granule dosage form compound composition.

[0036] Example 4

[0037] To further improve the water solubility and oral absorption rate of deacetylated shikimic acid, this embodiment first pre-treats the DAA with β-cyclodextrin inclusion complex before compounding it with other ingredients. The final compound contains the same proportions of active ingredients as in Example 1 (i.e., equivalent to 60 g of deacetylated shikimic acid, 10 g of 5-O-caffeoylshikimic acid, 10 g of neolansinoside, 10 g of coreopyridine, and 10 g of puerarin), but the deacetylated shikimic acid is added in the form of an inclusion complex.

[0038] The preparation steps are as follows: (1) Weigh 60 g of deacetylated cypermethrin and weigh 240 g of β-cyclodextrin according to the molar ratio of DAA to β-cyclodextrin of 1:2. (2) Add β-cyclodextrin to 3000 mL of hot purified water at 60℃ and stir to prepare a saturated solution; (3) Dissolve DAA in 200 mL of anhydrous ethanol and slowly add it dropwise to the above β-cyclodextrin solution. Stir in a constant temperature water bath at 60 °C for 3 hours. (4) Allow to cool naturally to room temperature, then continue stirring overnight (12 hours) to allow precipitation; (5) Filter and collect the precipitate, wash it twice with a small amount of purified water and anhydrous ethanol, dry it under vacuum at 45°C, pulverize it through a 100-mesh sieve, and obtain DAA-β-cyclodextrin inclusion complex powder (theoretical yield about 280 g). (6) Mix the above inclusion compound powder with 10 g of 5-O-caffeoylshikimic acid, 10 g of neolansinoside, 10 g of quinquercetin and 10 g of puerarin, and add excipients, granulate and encapsulate according to steps (3) to (5) of Example 1 to obtain a compound composition capsule containing cyclodextrin inclusion.

[0039] Example 5: Effects of core active ingredients on NAMPT expression and NAD+ The Influence of NADH Balance

[0040] The AC16 human cardiomyocyte cell line was used as a model for validation. AC16 cells were routinely cultured in DMEM / F12 medium containing 10% fetal bovine serum and incubated at 37°C in a 5% CO2 incubator.

[0041] Logarithmic growth phase AC16 cells were seeded into culture plates. NAMPT expression detection: AC16 cells were treated with 30 μmol / L deacetylated cypermethrin for 72 hours, cell lysates were collected, and NAMPT expression was detected by enzyme-linked immunosorbent assay (ELISA).

[0042] NAD + / NADH balance assay: A myocardial energy metabolism injury model was established by inducing myocardial energy metabolism injury with isoproterenol (ISO, final concentration 40 μmol / L), while simultaneously treating the patient with 30 μmol / L desacetylated rutin for 72 hours. There were three groups: a normal control group (NC), an injury model group (ISO only), and a DAA treatment group (ISO+DAA). Cells were collected after treatment, and NADPH balance was measured. + / NADH colorimetric test kit detects NAD in each group + / NADH ratio.

[0043] Table 1

[0044] The results showed that NAMPT expression in the deacetylated cypermethrin-treated group increased to approximately twice that of the control group, indicating that deacetylated cypermethrin can significantly upregulate NAD. + Rescue expression of the rate-limiting enzyme NAMPT.

[0045] Normal control group NAD + The NADH / g / g ratio was 6.63; in the damage model group, it dropped sharply to 0.018, falling to about 0.3% of the normal level, suggesting that cellular NAD+ levels were significantly reduced. + The pool is severely depleted; DAA treatment group NAD + The NAD / NADH ratio significantly recovered to 3.09, returning to approximately 47% of normal levels, an improvement of about 170-fold compared to the injury model group. These results indicate that deacetylated cypermethrin can promote NAD / NADH absorption by upregulating NAMPT expression. + Rescue synthesis effectively restores NAD in cardiomyocytes + / NADH balance.

[0046] In addition, the effect of 0-100 μmol / L deacetylated cypermethrin on the viability of AC16 cells was detected by the CCK-8 assay. The results showed that cell viability remained normal at this concentration, indicating that deacetylated cypermethrin has good safety.

[0047] Table 2

[0048] Example 6: Activity Verification of the Compound Composition

[0049] Following the same experimental procedure as in Example 5, the experimental grouping design was as follows: (1) normal control group; (2) injury model group (ISO 40 μmol / L); (3) DAA alone group; (4) each single auxiliary component group; (5) the compound composition of the present invention group (prepared according to the ratio in Example 1). Each group was administered the same total concentration, and after 72 hours of treatment, NAD+ was used. + / NADH colorimetric test kit detects NAD in each group + The / NADH ratios are shown in Table 3.

[0050] Table 3

[0051] According to the experimental results in Table 3, the normal control group maintained a stable high redox balance, while the damaged model group experienced a near-complete collapse of the balance due to severe stimulation, indicating significant disruption of myocardial energy metabolism. Against this backdrop, the core ingredient, deacetylated cypermethrin, alone could partially restore the damaged ratio, but not completely. While the four single auxiliary ingredients showed varying degrees of improvement, their recovery effects were weaker than those of the core ingredient. In contrast, the compound combination group exhibited the best recovery effect, with its improvement far exceeding that of any single ingredient, and essentially restoring the condition to a steady-state level comparable to the normal control group. This result fully demonstrates that the five active ingredients are not simply additive, but rather exhibit a significant synergistic effect. Through multi-target, multi-pathway systemic regulation, it ultimately achieved efficient reversal and repair of myocardial energy metabolism disorders.

[0052] Example 7: Pharmacodynamic evaluation of the compound composition in an animal model of myocardial energy metabolism disorder

[0053] This embodiment aims to verify the effect of the compound composition of the present invention on improving myocardial energy metabolism disorders and heart failure phenotypes related to circadian rhythm disorders, and further confirms its effectiveness through in vivo animal experiments.

[0054] 1. Laboratory animals and model construction

[0055] Eight-week-old Rev-Erbα / β double knockout (DKO) Myh6-cre transgenic mice were used. In this mouse model, Rev-Erbα / β was specifically knocked out in cardiomyocytes after tamoxifen induction, resulting in abnormally high expression of the key circadian rhythm transcription factor E4BP4, thereby mimicking the myocardial energy metabolism disorder and dilated cardiomyopathy (DCM) phenotype caused by circadian rhythm disturbance.

[0056] Mice were injected with tamoxifen (75 mg / kg / day, intraperitoneal injection) for 5 consecutive days starting at week 8 to induce gene knockout. After echocardiography confirmed the presence of DCM and heart failure phenotypes in the mice at week 24, drug intervention experiments were initiated.

[0057] 2. Experimental grouping and dosing regimen

[0058] Mice that successfully developed the model were randomly divided into 3 groups (n=8-10 in each group): DCM-Vehicle group (model control group): The same volume of solvent (physiological saline containing 10% DMSO) was administered by gavage.

[0059] Drug-ZT0 group (compound drug dawn administration group): The compound composition of the present invention (prepared according to the ratio of Example 1) was administered by gavage at the time of the time factor (ZT0, i.e., the simulated time of dawn) at a dose of 30 μmol / kg.

[0060] Drug-ZT12 group (compound drug evening administration group): The same dose of the compound composition was administered by gavage at ZT12 (i.e., simulated dark time).

[0061] A separate group of wild-type mice without modeling was set up as the normal control group (NC group). All mice were administered the drug by gavage for 4 weeks at a dose of 30 μmol / kg, and echocardiography was performed weekly.

[0062] 3. Observation Indicators and Detection Methods

[0063] Echocardiography was performed using a small animal ultrasound imaging system (Vevo 2100). The following cardiac function parameters were measured and recorded: Left ventricular ejection fraction (LVEF): A core indicator reflecting the heart's pumping function.

[0064] Left ventricular end-systolic diameters (LVIDs): reflect changes in the diameter of the heart during systole.

[0065] Left ventricular end-diastolic diameter (LVIDd): reflects the change in the diameter of the heart during diastole.

[0066] 4. Experimental Results

[0067] (1) Recovery status of cardiac function ( Figure 2 A)

[0068] like Figure 2 As shown, before administration (0W), the LVEF of mice in the DCM-Vehicle group was significantly lower than that in the NC group, and the LVIDs and LVIDd were significantly increased, indicating that obvious heart failure and cardiac enlargement had occurred.

[0069] Four weeks after administration (4 weeks), the cardiac function of mice in the DCM-Vehicle group continued to deteriorate, with a persistent decrease in LVEF and further ventricular enlargement. In contrast, the combined drug intervention groups (Drug-ZT0 and Drug-ZT12) both showed significant improvements in cardiac function. LVEF ( Figure 2 B): The LVEF of the drug group was significantly higher than that of the DCM-Vehicle group at 2, 3, and 4 weeks of administration (P<0.05 or P<0.01), indicating that the compound composition can effectively improve the pumping function of heart failure mice. Moreover, the improvement trend of the Drug-ZT0 group (administered at dawn) was better than that of the Drug-ZT12 group, suggesting that the regulatory effect of this compound on circadian rhythm may be time-dependent.

[0070] Left ventricular end-systolic diameters (LVIDs) Figure 2 C): At 3 and 4 weeks after administration, the LVIDs of mice in the drug group were significantly lower than those in the DCM-Vehicle group, indicating that the compound drug can inhibit or reverse pathological ventricular remodeling and improve myocardial contractile function.

[0071] Left ventricular end-diastolic diameter (LVIDd) Figure 2 D): The LVIDd of mice in the drug group did not show the sustained expansion seen in the model group after drug administration, and was lower than that in the DCM-Vehicle group, indicating that ventricular dilation was effectively controlled.

[0072] 5. Conclusion

[0073] This embodiment demonstrates through in vitro and in vivo experiments that the natural compound composition provided by this invention can: significantly upregulate NAMPT expression in cardiomyocytes and restore the NAD+ / NADH redox balance; effectively improve left ventricular systolic function in Rev-Erbα / β knockout-induced heart failure mice and inhibit ventricular remodeling; and exhibit good therapeutic and preventive effects on myocardial energy metabolism disorders caused by circadian rhythm disturbances.

[0074] In summary, this embodiment further verifies the application value of the composition of the present invention in the preparation of functional products for improving myocardial energy metabolism and treating heart failure.

[0075] The above description is only a preferred embodiment of the present invention. It should be noted that for those skilled in the art, several improvements and modifications can be made without departing from the principle of the present invention, and these improvements and modifications should also be considered within the scope of protection of the present invention.

Claims

1. A natural compound composition for improving myocardial energy metabolism, characterized in that, It includes the following active ingredients: deacetylated shikimic acid, 5-O-caffeoyl shikimic acid, neolansinoside, coreopioid, and puerarin.

2. The natural compound composition according to claim 1, characterized in that, The weight parts of each active ingredient are: deacetylated shikimic acid 40-80 parts, 5-O-caffeoyl shikimic acid 5-20 parts, neolansinoside 5-20 parts, coreopyroside 5-20 parts, and puerarin 5-20 parts.

3. The natural compound composition according to claim 1, characterized in that, The weight parts of each active ingredient are: 60 parts of deacetylated shikimic acid, 10 parts of 5-O-caffeoyl shikimic acid, 10 parts of neolansinoside, 10 parts of coreopsis glycoside, and 10 parts of puerarin.

4. The natural compound composition according to claim 1, characterized in that, The deacetylated cypermethrin is a deacetylated cypermethrin-cyclodextrin inclusion complex treated with cyclodextrin.

5. The natural compound composition according to claim 4, characterized in that, The cyclodextrin is β-cyclodextrin or hydroxypropyl-β-cyclodextrin, and the molar ratio of deacetylated cyclodextrin to cyclodextrin is 1:1~2.

6. A method for preparing the natural compound composition according to any one of claims 1 to 5, characterized in that, Includes the following steps: (1) Take acetyl shikimic acid, 5-O-caffeoyl shikimic acid, neolansinoside, coreopyridine and puerarin by weight respectively, mix them evenly to obtain a mixture; (2) Add excipients to the mixture and mix to prepare a formulation.

7. The method according to claim 6, characterized in that, Before mixing, the deacetylated cytosolic acid described in step (1) is first subjected to cyclodextrin inclusion treatment, specifically including: weighing deacetylated cytosolic acid and β-cyclodextrin in a molar ratio of 1:1~2, dissolving β-cyclodextrin in hot water at 50~60℃ to prepare a saturated solution, dissolving deacetylated cytosolic acid in ethanol and then adding it dropwise to the β-cyclodextrin solution, stirring and collecting the precipitate to obtain deacetylated cytosolic acid-β-cyclodextrin inclusion complex powder.

8. The method according to claim 7, characterized in that, The stirring process involves first stirring at a constant temperature of 50-60°C for 2-4 hours, then continuing to stir overnight after cooling.

9. The use of the natural compound composition according to any one of claims 1 to 5 in the preparation of a functional product for improving myocardial energy metabolism.

10. The application according to claim 9, characterized in that, The functional product is used to improve myocardial energy metabolism disorders caused by circadian rhythm disorders, long-term sleep deprivation, or shift work.